Astrocytoma: Causes, Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Astrocytomas are primary brain tumors arising from astrocytes — the star-shaped glial support cells of the central nervous system that maintain synaptic homeostasis, provide metabolic support to neurons, and form the blood-brain barrier. They constitute approximately 60% of all gliomas and represent the largest category of primary malignant brain tumors in adults. The WHO 2021 Classification of CNS Tumors fundamentally revised astrocytoma categorization by integrating molecular markers with histological assessment: IDH1/IDH2 mutation status is now the primary diagnostic discriminator, distinguishing IDH-mutant astrocytomas (generally lower-grade, better prognosis) from IDH-wildtype astrocytomas (universally grade 4 glioblastoma when histologically malignant, poor prognosis). IDH-mutant astrocytomas are graded 2-4 based on histological features and CDKN2A/2B homozygous deletion (grade 4 IDH-mutant regardless of histology). Glioblastoma (GBM, IDH-wildtype, grade 4) is the most common and lethal primary brain cancer — with approximately 14,500 new US cases annually, a median overall survival of 14-17 months despite aggressive treatment (Stupp protocol: surgery plus concurrent chemoradiation plus adjuvant temozolomide plus tumor treating fields), and fewer than 6% of patients surviving 5 years. Pilocytic astrocytoma (WHO grade 1, IDH-wildtype) represents the most common astrocytoma of childhood — typically indolent, often cystic, BRAF-KIAA1549 fusion-driven, and potentially curable by complete surgical resection alone.

The vast majority of astrocytomas arise sporadically from somatic mutations without an identifiable hereditary predisposition or modifiable environmental cause. Ionizing radiation is the only well-established environmental risk factor — therapeutic brain radiation (e.g., cranial irradiation for childhood ALL or brain metastases) increases the risk of secondary glioma, typically appearing 10-20 years after exposure. Genetic predisposition syndromes: neurofibromatosis type 1 (NF1, chromosome 17q11.2, neurofibromin gene mutation — autosomal dominant): strongly predisposes to optic pathway gliomas (WHO grade 1 pilocytic astrocytoma) and brain stem gliomas in children; Li-Fraumeni syndrome (TP53 germline mutation, chromosome 17p13.1): elevated risk for glioma and other cancers; tuberous sclerosis (TSC1/TSC2 mutations): predisposes to subependymal giant cell astrocytoma (SEGA) — a distinctive WHO grade 1 tumor requiring mTOR inhibitor therapy; Lynch syndrome: modestly elevated glioma risk. Key molecular pathogenesis: IDH1 (most commonly codon R132H point mutation) or IDH2 (codon R172) mutations are founding events in lower-grade astrocytoma — present in approximately 80% of grade 2-3 astrocytomas and grade 4 IDH-mutant GBM — producing the oncometabolite 2-hydroxyglutarate (2-HG) which inhibits alpha-ketoglutarate-dependent dioxygenases, causing genome-wide CpG island methylation (CIMP phenotype) and chromatin remodeling. Glioblastoma (IDH-wildtype) pathogenesis involves: EGFR amplification and EGFRvIII deletion variant (~50%); TERT promoter mutations (~70%); PTEN deletion (~40%); TP53 mutation; RB pathway loss; and CDKN2A/B deletion. MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation — present in approximately 45% of GBM — predicts sensitivity to temozolomide and is the single most important prognostic biomarker in GBM.

Clinical presentation reflects the tumor's grade, anatomical location, rate of growth, and degree of surrounding edema and mass effect. Seizures: a presenting feature in approximately 30-50% of low-grade astrocytomas and 20-25% of GBMs — particularly in patients with tumors involving the motor cortex, temporal lobe, or insular cortex; cortical irritation from diffuse infiltration of the astrocytoma. Headache: the most common symptom overall (~60% of patients) — typically gradual in onset, bilateral, worse in the morning (from increased ICP during recumbent sleep), aggravated by coughing, sneezing, or Valsalva maneuver, and may be accompanied by nausea and vomiting; severe headache with papilledema (bilateral disc swelling from elevated intracranial pressure) suggests significant mass effect. Focal neurological deficits: depend on tumor location — frontal lobe (contralateral hemiparesis, expressive aphasia, personality changes, frontal release signs); temporal lobe (receptive aphasia, memory impairment, contralateral superior quadrantanopia); parietal lobe (contralateral sensory loss, spatial neglect, dyspraxia, Gerstmann syndrome); occipital lobe (contralateral homonymous hemianopia); cerebellar astrocytoma (ipsilateral limb ataxia, gait unsteadiness, dysarthria, nystagmus); brain stem astrocytoma (cranial nerve palsies, long tract signs). Cognitive changes: memory loss, executive function impairment, decreased processing speed, and behavioral/personality changes — often the most disabling and distressing symptoms for patients and families. Symptoms of raised intracranial pressure (ICP) — progressive headache, nausea, vomiting, papilledema, and in severe cases Cushing's triad (hypertension, bradycardia, irregular respirations) — indicate urgent intervention. GBM hallmark: explosive neurological deterioration over days to weeks, reflecting rapid growth and extensive surrounding vasogenic edema.

MRI brain with and without gadolinium contrast is the gold standard neuroimaging modality — it provides superior anatomical detail compared to CT and is essential for surgical planning. MRI sequences: T2/FLAIR (fluid-attenuated inversion recovery) hyperintensity depicts tumor infiltration margins and surrounding edema — low-grade astrocytomas (WHO 2-3) typically show non-enhancing T2/FLAIR hyperintensity reflecting diffuse infiltration without breakdown of the blood-brain barrier; glioblastoma (WHO 4) demonstrates a heterogeneous mass with ring-enhancing contrast-enhancing component around a central core of necrosis, surrounded by extensive T2/FLAIR edema; DWI (diffusion-weighted imaging) and perfusion MRI (rCBV) help distinguish grade and tumor from non-tumor mimics (abscess, primary CNS lymphoma, metastasis, radiation necrosis). Advanced MRI techniques: MR spectroscopy (choline/N-acetylaspartate ratio elevation; IDH-mutant tumors show 2-HG peak); FET-PET (18F-fluoroethyltyrosine PET) or 18F-DOPA-PET for GBM extent beyond FLAIR signal. Tissue biopsy is mandatory for definitive diagnosis: stereotactic needle biopsy (minimally invasive, for deep or eloquent location tumors) or open craniotomy with surgical resection (provides maximum tissue for molecular profiling and therapeutic cytoreduction). Mandatory molecular profiling per WHO 2021: IDH1/IDH2 mutation (sequencing of codon R132/R172); MGMT promoter methylation status (pyrosequencing — critical for GBM treatment decision); CDKN2A/B homozygous deletion (FISH — establishes grade 4 IDH-mutant astrocytoma); TERT promoter mutation; ATRX loss (IHC — associated with IDH-mutant astrocytoma); 1p/19q codeletion (FISH — present in oligodendroglioma, not astrocytoma); H3K27M mutation (characteristic of diffuse midline glioma, not conventional astrocytoma). EGFR amplification, PTEN loss, and whole-genome methylation profiling are performed in select cases or research contexts.

Treatment is comprehensively guided by WHO grade, IDH status, MGMT status, patient age, performance status, and eloquent brain location. Grade 1 pilocytic astrocytoma (IDH-wildtype, typically pediatric/young adult): complete surgical resection is curative in approximately 90% of cases (>95% 5-year survival); radiotherapy reserved for incompletely resected, recurrent, or unresectable disease; BRAF inhibitors (dabrafenib plus trametinib) for BRAF V600E-mutated pilocytic astrocytomas not amenable to surgery. Grade 2 IDH-mutant astrocytoma: maximal safe surgical resection (maximized with awake craniotomy in eloquent areas); observation after resection for low-risk patients (age below 40, complete resection) — 5-year PFS approximately 50% with observation; radiotherapy (54 Gy) plus chemotherapy (PCV: procarbazine, lomustine, vincristine) for high-risk grade 2 (age above 40, incomplete resection, large tumor) — RTOG 9802 trial: 5.5-year PFS benefit with PCV versus RT alone; temozolomide is used as alternative to PCV based on EORTC 22033 trial. Grade 3 IDH-mutant anaplastic astrocytoma: maximal resection plus radiotherapy (60 Gy) plus temozolomide-based chemotherapy. Grade 4 GBM (IDH-wildtype) — Stupp protocol: maximal safe resection (5-ALA fluorescence guidance, intraoperative MRI, or awake craniotomy to maximize extent of resection); concurrent radiotherapy 60 Gy in 30 fractions with daily temozolomide 75 mg/m2; then adjuvant temozolomide 150-200 mg/m2 for 5/28-day cycles, 6 cycles; tumor treating fields (Optune/TTF device — wearable scalp electrodes delivering 200 kHz alternating electric fields) added for MGMT-methylated GBM (EF-14 trial: median OS 20.9 vs 16.0 months with TTF plus temozolomide vs temozolomide alone); bevacizumab (anti-VEGF) approved for recurrent GBM — improves PFS but not OS (AvaBrain/BRAIN trials); lomustine (CCNU, 110 mg/m2 every 6 weeks) as second-line salvage. IDH-mutant-targeted therapy: vorasidenib (IDH1/2 dual inhibitor) significantly improved PFS versus placebo in grade 2 IDH-mutant glioma — FDA approved 2024 (INDIGO trial: PFS 27.7 vs 11.1 months); ivosidenib for IDH1-mutant recurrent disease. Dexamethasone: started perioperatively to reduce vasogenic edema (typically 4 mg four times daily); tapered as quickly as possible given steroid side effects.

Prognosis in astrocytoma varies dramatically by WHO grade and IDH mutation status — the two most important prognostic determinants in the WHO 2021 classification. Pilocytic astrocytoma (WHO grade 1, IDH-wildtype, primarily pediatric): 5-year overall survival exceeds 95% with complete surgical resection; long-term cure rates approach 90% even for incompletely resected tumors reflecting benign biology. IDH-mutant astrocytoma grade 2: median overall survival approximately 10-15 years from diagnosis; 5-year survival approximately 70-80%; progression to higher grade occurs in approximately 50-70% of patients over 5-10 years, particularly in those with 1p/19q non-co-deleted status. IDH-mutant astrocytoma grade 3 (anaplastic): median OS approximately 4-8 years; 5-year survival approximately 40-55% with radiotherapy plus chemotherapy (temozolomide or PCV). IDH-mutant grade 4 astrocytoma: median OS approximately 2-4 years. Glioblastoma (IDH-wildtype, grade 4): median OS approximately 14-17 months with Stupp protocol (surgery plus concurrent chemoradiation plus adjuvant temozolomide); 5-year survival below 6%. MGMT promoter methylation is the most important prognostic biomarker within GBM — methylated patients achieve median OS of approximately 21 months versus 12-14 months for unmethylated. Tumor treating fields (Optune) added to adjuvant temozolomide improve 5-year survival from 5.1% to 13.0% in the EF-14 trial. Recurrent GBM carries median post-progression survival of approximately 6-9 months with current therapies. Key prognostic factors across all grades include IDH mutation status, MGMT methylation, extent of surgical resection, patient age, and performance status. Long-term survivors of lower-grade astrocytoma require monitoring for cognitive effects of treatment and late recurrence.

The only established preventable risk factor for astrocytoma is therapeutic ionizing radiation to the brain — which should only be used when the clinical benefit clearly outweighs the risk. Most astrocytomas arise from sporadic mutations without identifiable preventable cause. Individuals with hereditary syndromes predisposing to astrocytoma — NF1, Li-Fraumeni syndrome (TP53 mutation), and tuberous sclerosis — should receive regular neurological monitoring and MRI surveillance as part of their syndrome-specific care plan. Routine mobile phone use has not been established as a risk factor in large prospective studies. Currently, no dietary, lifestyle, or chemoprevention strategy is proven to reduce astrocytoma risk.

New-onset seizures in an adult — particularly a first unprovoked seizure — require urgent brain imaging to exclude an underlying structural cause including astrocytoma. Progressive headache that is worst in the morning, or that awakens a person from sleep, warrants neurological evaluation — this pattern suggests raised intracranial pressure. Any new focal neurological deficit (weakness on one side, speech difficulty, visual changes, loss of coordination) of subacute onset should be evaluated urgently with brain MRI. Personality changes, memory disturbance, or behavioural abnormalities that represent a clear change from baseline — especially in an otherwise well adult — require neurological assessment. Children with unexplained cerebellar ataxia (gait unsteadiness) or persistent headache and vomiting need urgent paediatric neurological evaluation.